FILTER

Refine your search with the following facets to narrow down your results.

203 Current news of Frost & Sullivan

Global Pharmaceutical and Biotechnology Industry Boosts Confidence for Investors as the Market Expands

Companies are exploring new markets for innovative assets to add value to their pipeline, finds Frost & Sullivan

31-Jul-2015 - In recent years, the global pharmaceutical and biotechnology industry has outperformed other sectors in terms of stock market indices. The appeal of orphan drugs and systems that reduce the cost of healthcare will continue to attract investors to fund the industry.Analysis from Frost & Sullivan, ...

biotechnology Frost & Sullivan healthcare +2

Orthobiologics Are the Future for Bone Healing

Innovations in biomaterials, graft design and other technologies have pushed these products to the forefront of the industry, says Frost & Sullivan

23-Jul-2015 - Autografts, the gold standard of bone grafts, have several limitations. As a result, new orthobiologics products are being developed for the benefit of patients as well as surgeons. Innovations in biomaterials and graft design have enabled these advanced products that mimic the natural human bone ...

bone grafts Frost & Sullivan market researches

Small Animal Imaging Crucial for Drug Development and Non-Invasive Identification of Diseases in Humans

Animal models are an efficient and cost-effective way to understand underlying mechanisms of several human conditions

16-Jul-2015 - The use of small animal models in basic and preclinical research is now an integral part of developing and testing new pharmaceutical drugs prior to commercialisation. Small animal imaging is an efficient and cost-effective research platform for the timely validation and commercialisation of ...

animal models drug development drug discovery +1

Drug Abuse Triggers Regulations to Push the Development of Tamper-Resistant Opioid Formulations for Pain Management

Targeted pain drugs that do not have side effects such as constipation and addiction have a huge market awaiting them, says Frost & Sullivan

09-Jun-2015 - The pain market is currently dominated by opioid analgesics, which have well-known side effects such as addiction and constipation. However, a $10 billion market exists for a company able to develop a novel, targeted pain therapy that excludes these side effects, indicating the huge opportunity ...

addiction constipation drug abuse +4

Recombinant and Prophylactic Treatments Boost Global Haemophilia Therapeutics Market

Haemophilia B segment will see high growth over the forecast period, finds Frost & Sullivan

11-May-2015 - Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to ...

Frost & Sullivan hemophilia A hemophilia B +2

Development and Commercialization of Antibacterial Drugs to Speed Up

The recently implemented GAIN Act is expected to lure companies back into R&D as well as attract new participants, finds Frost & Sullivan

07-Apr-2015 - The growing threat posed by multi-drug resistant gram-negative organisms (MDR-GNBs) is lending a sense of urgency to the development of antibacterial drugs worldwide. Upcoming regulatory reforms to lower R&D costs and provide incentives for new drug identification will create attractive ...

antibiotic resistance antibiotics drug resistance +1

Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments

Close competition encourages established manufacturers to broaden the drug pipeline for targeted therapies, finds Frost & Sullivan

05-Mar-2015 - Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in the market for its treatment. Further, popular drugs such as Almita and Avastin are nearing their patent expiry in 2015 and 2017 respectively. As such, the lung cancer therapeutics market offers ...

cancer therapeutics Frost & Sullivan lung cancer +3

Healthcare is up for a Revolution with the Rise of Personal Genomic Tests

Frost & Sullivan finds that direct to consumer genomics, which were close to absent a decade ago, are currently thriving

26-Feb-2015 - As the era of personalized medicine dawns on healthcare, the need to understand an individual’s genetic information through genomic testing has risen. This emerging branch of medicine has given birth to multiple companies that provide genetic tests to help end users understand their genetic ...

Frost & Sullivan genome sequencing genomics +1

Turkish Life Sciences Industry Fuelled by Favourable Investment Climate and Healthcare Reforms

Biologics, oncology drugs and blood-based products will be key revenue-generating segments, finds Frost & Sullivan

13-Jan-2015 - Big pharmaceutical companies and foreign investors are flocking to Turkey to capitalise on its encouraging economic policies. The establishment of technology development zones that exempt pharmaceutical entrepreneurs and academics from income taxes until 2023 has played a particularly crucial ...

clinical diagnostics Frost & Sullivan market researches +2

Molecular Methods Rapidly Gain Ground in Infectious Disease Diagnostics

Convergence of immunodiagnostic and molecular tests will help meet demand in developed countries, says Frost & Sullivan

16-Dec-2014 - Unique disease outbreaks across the globe are escalating the demand for screening and spurring the infectious disease diagnostic market. The market will continue to develop as unmet technological needs lead to the creation of faster, more capable platforms. Molecular diagnostics is growing the ...

diagnostic tests diagnostics Frost & Sullivan +6